First Biosimilar Reviews Raise Questions About the Differences
This article was originally published in The Gold Sheet
Executive SummaryDRUGS WON'T BE QUITE THE SAME in a biosimilar world, but does it really matter? Without better analytical technology, only clinical trials and post-marketing surveillance will tell. Global regulators are beginning to decide which differences they will allow, and on what basis. Recent approvals in India and China draw criticism at WCBP 2008 from Genentech official who explores uncertainties about growth hormones, other recombinants. The EU's new biosimilars framework and first approvals and denials are explained. Meanwhile, follow-on biologics regulation is planned by the World Health Organization, Japan and the U.S.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.